hVIVO’s Dr Rob Lambkin-Williams making oral presentation at Human Antibodies & Hybridomas (“HAH 2016”), Belfast, November 2016

November 4, 2016 3:04 pm

HAH 2016, 9 – 11 November 2016, Hilton Hotel, Belfast, Northern Ireland, UK 

Dr Rob Lambkin-Williams, hVIVO’s Executive Scientific Advisor, will be making an oral presentation at HAH 2016, this the 20th conference of its kind including lectures, contributed papers and poster presentations emphasising all key aspects of human antibody and hybridoma technology, applications and engineering. The event takes place between 9th and 11th November 2016 in Belfast, Northern Ireland, and is organised by Meetings Management.

Dr Lambkin-William’s hVIVO oral presentation, taking place on Day 2, Thursday 10th November (SESSION 7: 14.30-15.00) is entitled “Proof of concept studies for monoclonal antibodies against respiratory viruses”.

Commenting on this year’s HAH 2016 event, Dr Rob Lambkin-Williams said “I am delighted to be asked to speak at HAH. Monoclonal antibodies were a game changer in the treatment of RSV and are currently the only licensed treatment for children; recent studies have shown that similar antibodies could also revolutionise the treatment of flu.”

If you would like to make contact with Dr Rob Lambkin-Williams from hVIVO before or during the HAH event in Belfast, please use the contact form below.

Find out more about ‘HAH 2016’ here.

Comments are closed here.